BMI was lower after treatment in aggregated lipodystrophy, in generalized and partial subgroups, and in those with LMNA or BSCL2 mutations, but not PPARG or AGPAT2 mutations (Level 3 evidence, Supplementary Data 3, Fig. 2). This evidence concerns the gene AGPAT2 and lipodystrophy.